Well, my brain thread would start with the idea that our Excellagen sales blip in late 2019 ($400k in one month, per Joe) would have continued to become a legit revenue stream. We would now be selling probably millions of dollars' worth of that product now per month. This would have allowed Joe to avoid several of the dirty financing deals he had to enter to keep us afloat. The Excellagen success could have possibly led to a slow rollout of other product lines across other business units over the course of this year. Maybe we would have even seen progress in AZ, and parts of that would have produced revenue this year?

As far as NGIO, the plan was always to spin it off based on AE37 cancer trials, and the valuation from non-CV potential. Given the 10-year data on AE 37, this would presumably have still happened... although maybe we will see better results of the spinoff if it now coincides with some CV success.